Artiva Biotherapeutics filings document its clinical-stage biotechnology business, Nasdaq-listed common stock and material-event reporting. Recent Form 8-K disclosures cover quarterly and annual financial results, Regulation FD updates on AlloNK® (AB-101) clinical data, and exhibits such as press releases and corporate presentations.
The filing record also describes governance and compensation matters, including board and officer appointments, employment arrangements, non-employee director compensation, inducement awards and an option-for-RSU exchange under the 2024 Equity Incentive Plan. Artiva’s disclosures identify AlloNK as an off-the-shelf NK cell therapy candidate used with anti-CD20 monoclonal antibodies in autoimmune-disease trials, alongside standard public-company capital-structure and securities information.
Artiva Biotherapeutics, Inc. (ARTV) Chief Executive Officer and director Fred Aslan sold 23,463 shares of common stock on October 6, 2026, at a weighted average price of $7.1977 per share; individual sale prices ranged from $6.92 to $7.36. The sale was made pursuant to a Rule 10b5-1 plan adopted on May 13, 2026. His reported direct holdings after the transaction were 1,519,606 shares.
Artiva Biotherapeutics, Inc. (ARTV) reports a proposed sale by Fred Aslan, identified as a director and officer, of 34,465 common shares with an aggregate market value of $245,735.45; the approximate sale date is October 6, 2026, through Morgan Stanley Smith Barney LLC. The shares were or will be acquired upon vesting of restricted stock units during August 15, 2025, through October 1, 2026. A past-three-months section titled “10b5-1 Sales” lists Fred Aslan sales of 23,429 shares for $255,746.28 on September 8, 2026, and 61,888 shares for $690,391.58 on September 3, 2026.
Christopher Horan, Artiva Biotherapeutics, Inc. (ARTV)’s Chief Tech Operations Officer, sold 10,340 shares of common stock on October 5, 2026, at $6.8372 per share. He held 312,744 shares directly following the sale. The transaction was automatic under the issuer’s sell-to-cover policy to satisfy tax withholding obligations connected with the vesting and release of restricted stock units, and was not at his discretion.
Artiva Biotherapeutics, Inc. COO, CLO and Compliance Officer Jennifer Bush sold 8,370 shares of common stock on October 5, 2026, at $6.8372 per share, leaving her with 366,159 shares held directly. The sale was automatic under the issuer’s sell-to-cover policy to meet tax withholding obligations related to the vesting and release of restricted stock units, and was not at her discretion. No Rule 10b5-1 plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) Chief Medical Officer Subhashis Banerjee sold 1,099 common shares on October 5, 2026, at $6.8372 per share. The sale was automatic under the issuer’s sell-to-cover policy to meet tax-withholding obligations tied to the vesting and release of restricted stock units; it was not at Banerjee’s discretion. He held 169,848 shares directly after the sale. No Rule 10b5-1 plan is reported.
Artiva Biotherapeutics, Inc. CEO and director Fred Aslan reported selling 61,696 common shares on October 5, 2026, at $6.8372 per share. The sale was automatic under the issuer’s sell-to-cover policy to meet tax withholding obligations connected with vesting and release of restricted stock units, and was not at his discretion. He directly held 1,543,069 shares after the sale. No Rule 10b5-1 plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Executive Officer Fred Aslan received new equity awards on September 15, 2026. He was granted 110,000 shares of Common Stock as a restricted stock unit award under the company’s 2024 Equity Incentive Plan, increasing his direct Common Stock holdings to 1,604,765 shares after the grant.
He was also granted an option to acquire 315,000 shares of Common Stock at an exercise price of $8.91 per share, expiring September 14, 2036. Beginning on September 8, 2026, 1/48th of the option shares will vest in equal monthly installments over four years. No Rule 10b5-1 trading plan is reported for these awards.
Artiva Biotherapeutics, Inc. (ARTV) reported that its Chief Executive Officer, Fred Aslan, received equity awards on September 10, 2026. He was granted 155,000 stock options with an exercise price of $10.42 per share, expiring on September 9, 2036, and a separate award of 45,000 restricted stock units under the 2024 Equity Incentive Plan. Following the restricted stock unit grant, Aslan directly holds 1,494,765 shares of common stock. The stock options begin vesting on September 8, 2026 in equal monthly installments over four years. No Rule 10b5-1 trading plan is reported for these awards.
Artiva Biotherapeutics, Inc. (ARTV) reported an indirect acquisition of a director stock option related to board member Laura Stoppel. On September 10, 2026, an option for 16,250 shares of common stock was granted with an exercise price of $10.42 per share and no upfront cost. The option vests on the earlier of September 10, 2027 or the company’s 2027 annual stockholder meeting, subject to Dr. Stoppel’s continued board service, and expires on September 9, 2036. Under her arrangement with RA Capital entities, any net value from this option is turned over to those funds, and the reporting persons disclaim beneficial ownership.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Laura Stoppel received a grant of 16,250 Director Stock Options on September 10, 2026. The options have an exercise price of $10.42 per share and expire on September 9, 2036.
The options will vest in full on the earlier of September 10, 2027 or the date of Artiva’s 2027 annual stockholder meeting. According to the disclosure, Stoppel holds this option for the benefit of funds and an account managed by RA Capital Management, L.P. and disclaims beneficial ownership of the option and underlying common stock. No Rule 10b5-1 trading plan is reported.